The stock of Onconova Therapeutics Inc (NASDAQ:ONTX) is a huge mover today! The stock decreased 5.02% or $0.14 during the last trading session, hitting $2.65. About 90,350 shares traded hands. Onconova Therapeutics Inc (NASDAQ:ONTX) has declined 42.39% since February 29, 2016 and is downtrending. It has underperformed by 52.82% the S&P500.
The move comes after 5 months negative chart setup for the $16.21M company. It was reported on Oct, 1 by Barchart.com. We have $2.28 PT which if reached, will make NASDAQ:ONTX worth $2.27 million less.
Analysts await Onconova Therapeutics Inc (NASDAQ:ONTX) to report earnings on November, 9.
According to Zacks Investment Research, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company’s products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania.”
More notable recent Onconova Therapeutics Inc (NASDAQ:ONTX) news were published by: Fool.com which released: “Why Onconova Therapeutics Inc. Shares Imploded” on February 20, 2014, also Globenewswire.com with their article: “Onconova Therapeutics, Inc. Announces Appointment of Jack E. Stover to Board …” published on May 23, 2016, Globenewswire.com published: “Onconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective …” on May 20, 2016. More interesting news about Onconova Therapeutics Inc (NASDAQ:ONTX) were released by: Fool.com and their article: “Why Onconova Therapeutics Inc. Shares Crashed” published on December 18, 2013 as well as Nasdaq.com‘s news article titled: “Onconova Therapeutics, Inc. to Present Corporate Updates at Upcoming Investor …” with publication date: September 07, 2016.
ONTX Company Profile
Onconova Therapeutics, Inc., incorporated on December 22, 1998, is a clinical-stage biopharmaceutical company. The Firm operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Firm has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.